Denali Therapeutics (DNLI) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 124.5% versus a gain of 28.6%. Over five years, DNLI leads with a -57.9% price change compared with -80.0% for MRVI. Denali Therapeutics is the larger company by market cap ($3.06 billion vs $2.75 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | MRVI |
|---|---|---|
| Share price | $19.16 | $7.43 |
| Market cap | $3.06B | $2.75B |
| 1-day change | -0.62% | -5.35% |
| YTD return | +16.05% | +128.62% |
| 1-year return | +28.59% | +124.47% |
| 5-year return | -57.95% | -79.97% |
| EPS (TTM) | $-2.84 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $185.74M |
| Revenue growth (YoY) | — | -28.34% |
| Net income (latest FY) | $-512.54M | $-130.77M |
| Gross margin | — | 18.30% |
| Operating margin | — | -115.89% |
| Net margin | — | -70.41% |
| 52-week high | $27.30 | $9.42 |
| 52-week low | $13.75 | $2.55 |
| Distance from 52-week high | -29.82% | -21.13% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +88.20% | +5.38% |
| Average volume | 1.61M | 3.31M |
| Shares outstanding | 159.85M | 148.99M |
| Employees | 503 | 415 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed DNLI by 95.9 percentage points over the past year.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
DNLI vs MRVI FAQ
Which is bigger, Denali Therapeutics or Maravai LifeSciences?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $3.06B compared with $2.75B for Maravai LifeSciences (MRVI).
Which stock has performed better over the past year, DNLI or MRVI?
MRVI returned +124.47% over the past 12 months, compared with +28.59% for DNLI (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and Maravai LifeSciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Denali Therapeutics and Biotechnology: Pharmaceutical Preparations for Maravai LifeSciences.